Taiko Pharmaceutical Co.,Ltd. (4574.T)
JPY 260.0
(-2.62%)
JPY 260.0
(-2.62%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2022 | 5.04 Billion JPY | -52.99% |
| 2021 | 10.72 Billion JPY | -39.38% |
| 2020 | 17.68 Billion JPY | 18.4% |
| 2019 | 14.93 Billion JPY | 43.93% |
| 2018 | 10.37 Billion JPY | 9.95% |
| 2017 | 9.43 Billion JPY | 13.92% |
| 2016 | 8.28 Billion JPY | -0.13% |
| 2015 | 8.29 Billion JPY | -10.2% |
| 2014 | 9.23 Billion JPY | -6.39% |
| 2013 | 9.86 Billion JPY | 33.07% |
| 2012 | 7.41 Billion JPY | 10.83% |
| 2011 | 6.69 Billion JPY | 49.67% |
| 2010 | 4.47 Billion JPY | -48.81% |
| 2009 | 8.73 Billion JPY | 43.37% |
| 2008 | 6.09 Billion JPY | 9.91% |
| 2007 | 5.54 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q3 | 1.92 Billion JPY | 46.03% |
| 2023 Q2 | 1.32 Billion JPY | 13.2% |
| 2023 Q1 | 1.16 Billion JPY | -29.32% |
| 2022 Q3 | 1.53 Billion JPY | 23.95% |
| 2022 FY | 5.04 Billion JPY | -52.99% |
| 2022 Q4 | 1.65 Billion JPY | 7.77% |
| 2022 Q1 | 621 Million JPY | -73.26% |
| 2022 Q2 | 1.23 Billion JPY | 99.03% |
| 2021 Q1 | 3.27 Billion JPY | 0.0% |
| 2021 Q2 | 1.86 Billion JPY | -43.26% |
| 2021 FY | 10.72 Billion JPY | -39.38% |
| 2021 Q4 | 2.32 Billion JPY | -28.77% |
| 2021 Q3 | 3.26 Billion JPY | 75.27% |
| 2020 FY | 17.68 Billion JPY | 18.4% |
| 2020 Q1 | 4.92 Billion JPY | -12.63% |
| 2020 Q3 | 5.14 Billion JPY | -9.39% |
| 2020 Q2 | 5.67 Billion JPY | 15.26% |
| 2019 Q2 | 1.41 Billion JPY | -55.6% |
| 2019 FY | 14.93 Billion JPY | 43.93% |
| 2019 Q1 | 3.18 Billion JPY | -6.69% |
| 2019 Q3 | 2.95 Billion JPY | 109.09% |
| 2019 Q4 | 5.63 Billion JPY | 90.43% |
| 2018 Q4 | 3.41 Billion JPY | 36.34% |
| 2018 Q3 | 2.5 Billion JPY | 97.86% |
| 2018 Q1 | 2.73 Billion JPY | -10.96% |
| 2018 Q2 | 1.26 Billion JPY | -53.77% |
| 2018 FY | 10.37 Billion JPY | 9.95% |
| 2017 Q3 | 2.22 Billion JPY | 60.04% |
| 2017 Q2 | 1.39 Billion JPY | -37.2% |
| 2017 Q1 | 2.21 Billion JPY | -27.63% |
| 2017 FY | 9.43 Billion JPY | 13.92% |
| 2017 Q4 | 3.07 Billion JPY | 38.03% |
| 2016 Q4 | 3.06 Billion JPY | 57.21% |
| 2016 FY | 8.28 Billion JPY | -0.13% |
| 2016 Q3 | 1.94 Billion JPY | 85.15% |
| 2016 Q2 | 1.05 Billion JPY | -51.64% |
| 2016 Q1 | 2.17 Billion JPY | -24.32% |
| 2015 Q2 | 1.42 Billion JPY | -24.73% |
| 2015 Q1 | 1.89 Billion JPY | -46.55% |
| 2015 Q4 | 2.87 Billion JPY | 58.72% |
| 2015 FY | 8.29 Billion JPY | -10.2% |
| 2015 Q3 | 1.81 Billion JPY | 26.87% |
| 2014 Q4 | 3.55 Billion JPY | 60.47% |
| 2014 Q3 | 2.21 Billion JPY | 40.42% |
| 2014 Q1 | 2.28 Billion JPY | -33.17% |
| 2014 Q2 | 1.57 Billion JPY | -31.01% |
| 2014 FY | 9.23 Billion JPY | -6.39% |
| 2013 Q1 | 1.73 Billion JPY | -28.23% |
| 2013 FY | 9.86 Billion JPY | 33.07% |
| 2013 Q2 | 1.88 Billion JPY | 8.69% |
| 2013 Q4 | 3.41 Billion JPY | 49.68% |
| 2013 Q3 | 2.28 Billion JPY | 21.26% |
| 2012 Q4 | 2.41 Billion JPY | 30.49% |
| 2012 Q2 | 1.41 Billion JPY | -24.75% |
| 2012 FY | 7.41 Billion JPY | 10.83% |
| 2012 Q1 | 1.88 Billion JPY | 5.8% |
| 2012 Q3 | 1.84 Billion JPY | 30.29% |
| 2011 Q3 | 1.63 Billion JPY | 17.9% |
| 2011 Q2 | 1.38 Billion JPY | 79.11% |
| 2011 FY | 6.69 Billion JPY | 49.67% |
| 2011 Q1 | 774.01 Million JPY | -47.5% |
| 2011 Q4 | 1.78 Billion JPY | 9.1% |
| 2010 Q3 | 1.28 Billion JPY | 37.28% |
| 2010 Q1 | 731.12 Million JPY | -75.46% |
| 2010 Q4 | 1.47 Billion JPY | 14.69% |
| 2010 FY | 4.47 Billion JPY | -48.81% |
| 2010 Q2 | 936.44 Million JPY | 28.08% |
| 2009 Q4 | 2.97 Billion JPY | -2.74% |
| 2009 Q3 | 3.06 Billion JPY | 56.4% |
| 2009 Q2 | 1.95 Billion JPY | 36.93% |
| 2009 Q1 | 1.43 Billion JPY | -22.82% |
| 2009 FY | 8.73 Billion JPY | 43.37% |
| 2008 FY | 6.09 Billion JPY | 9.91% |
| 2008 Q4 | 1.85 Billion JPY | 0.0% |
| 2007 FY | 5.54 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 62.14 Billion JPY | 91.89% |
| Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 99.882% |
| Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 98.398% |
| Shionogi & Co., Ltd. | 435.08 Billion JPY | 98.842% |
| Wakamoto Pharmaceutical Co.,Ltd. | 7.73 Billion JPY | 34.87% |
| Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 96.6% |
| Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 93.004% |
| Eisai Co., Ltd. | 741.75 Billion JPY | 99.321% |
| Morishita Jintan Co., Ltd. | 12.4 Billion JPY | 59.374% |
| Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 96.443% |
| Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 95.101% |
| Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | 90.904% |
| Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | 83.609% |
| Tsumura & Co. | 150.84 Billion JPY | 96.659% |
| Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 93.331% |
| Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | 90.776% |
| Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 97.789% |
| Fuji Pharma Co., Ltd. | 40.88 Billion JPY | 87.674% |
| Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 93.344% |
| KYORIN Holdings, Inc. | 119.53 Billion JPY | 95.784% |
| Daito Pharmaceutical Co.,Ltd. | 46.89 Billion JPY | 89.253% |
| SymBio Pharmaceuticals Limited | 5.58 Billion JPY | 9.834% |
| MedRx Co., Ltd | 26 Million JPY | -19284.615% |
| Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | 54.139% |
| Solasia Pharma K.K. | 617 Million JPY | -716.856% |
| Modalis Therapeutics Corporation | - JPY | -Infinity% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 62.84 Billion JPY | 91.98% |
| Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 97.15% |
| Cyfuse Biomedical K.K. | 61.11 Million JPY | -8147.153% |
| Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 99.659% |
| Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | 77.23% |